Please assess the completion status of the following clinical trial:

Trial Title: the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female, aged ≥ 18 years old;~* Eastern Cooperative Oncology Group performance status (ECOG -PS) ≤ 1;~* Locally advanced or metastatic triple-negative breast cancer, i.e. HER2-negative status and ER and PgR negative status (as per local assessment);~* Treatment with 1st line chemotherapy (with any drug excepted Bevacizumab-based regimens) as per clinical practice, and non-progressive when the treatment was terminated;~* No more than 6 cycles of the previous chemotherapy;~* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1);~* Willingness and ability to comply with the study protocol as judged by the Investigator;~* For women who are not postmenopausal (i.e., \< 2 years after last menstruation) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the treatment period and for at least 6 months after the last dose of study drug;~* Provision of a written informed consent signed prior to enrolment according to ICH/GCP.~Exclusion Criteria:~* Previous treatment with vinorelbine or capecitabine;~* 1st line therapy with a bevacizumab-based regimen;~* Presence of brain metastases;~* Any other investigational drug or any anti-cancer treatment (except for radiotherapy, if the treatment field does not include the liver);~* Inadequate bone marrow, hepatic or renal function including the following:~  1. absolute neutrophils count of \< 1.5 cells x 109/L, platelet count \< 100 cells x 109/L, or hemoglobin \< 8 g/L;~ 2. serum total bilirubin \>1.5 × institution upper limit of normal \[ULN\], aspartate aminotransferase and alanine aminotransferase \>2.5 × ULN, or \>5 × ULN for patients with liver metastases, alkaline phosphatase \>2.5 × ULN, or \>5 × ULN for patients with liver metastases, or \>10 × ULN for patients with bone metastases;~ 3. serum creatinine concentration \>1.5 × ULN, creatinine clearance \<50 mL/min calculated according to Cockcroft-Gault equation, and coagulation parameters international normalized ratio \>1.5;~* With the exception of basal cell carcinoma or cervical cancer in situ, history of another malignancy, unless in remission for 5 years or more and judged of negligible potential of relapse;~* Known dihydropyrimidine dehydrogenase deficiency;~* Treatment with sorivudine or its chemically related analogues, such as brivudine, within 4 weeks prior to randomization;~* Evidence of any significant clinical disorder or concurrent illness or laboratory finding that, at the judgment of the Investigator, contra-indicate the inclusion of the patient in the study;~* Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study assessment and procedures;~* Unable to swallow tablets;~* Previous significant surgical resection of stomach or small bowel~* Patients requiring long-term oxygen therapy~* Known hypersensitivity to any excipients of oral vinorelbine, oral capecitabine and to fluoropyrimidine.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): Vinorelbine 50 mg, thrice a week
- ARM B (Type: EXPERIMENTAL): Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).